Page last updated: 2024-11-12
desacetylcinobufagin
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
desacetylcinobufagin: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 11877495 |
| CHEMBL ID | 465893 |
| MeSH ID | M0586526 |
Synonyms (9)
| Synonym |
|---|
| desacetylcinobufagin |
| 3-beta,16-beta-dihydroxy-14,15-beta-epoxy-5-beta-bufa-20,22-dienolide |
| CHEMBL465893 |
| CS-3699 |
| HY-N0881 |
| mfcd01740865 |
| 5-[(1r,2s,4r,5r,6r,7r,10s,11s,14s,16r)-5,14-dihydroxy-7,11-dimethyl-3-oxapentacyclo[8.8.0.02,4.02,7.011,16]octadecan-6-yl]pyran-2-one |
| MS-26814 |
| 5-[(1r,2s,4r,5r,6r,7r,10s,11s,14s,16r)-5,14-dihydroxy-7,11-dimethyl-3-oxapentacyclo[8.8.0.0,.0,.0,octadecan-6-yl]-2h-pyran-2-one |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Bioassays (6)
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID155910 | Inhibitory activity against the primary liver carcinoma (PLC) cell line PLC/PRF/5 | 2002 | Journal of medicinal chemistry, Dec-05, Volume: 45, Issue:25 | QSAR evaluation of the Ch'an Su and related bufadienolides against the colchicine-resistant primary liver carcinoma cell line PLC/PRF/5(1). |
| AID357630 | Cytotoxicity against mouse MH60 cells after 72 hrs by MTT assay | 2001 | Journal of natural products, Sep, Volume: 64, Issue:9 | Isolation and structure of five new cancer cell growth inhibitory bufadienolides from the Chinese traditional drug Ch'an Su. |
| AID357628 | Cytotoxicity against human KB cells after 72 hrs by MTT assay | 2001 | Journal of natural products, Sep, Volume: 64, Issue:9 | Isolation and structure of five new cancer cell growth inhibitory bufadienolides from the Chinese traditional drug Ch'an Su. |
| AID1221925 | Retention time in Sprague-Dawley rat liver microsomes treated with 100 uM cinobufagin at 37 degC after 30 mins by UFLC-DAD-ESI-MS analysis | 2011 | Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4 | Comparative metabolism of cinobufagin in liver microsomes from mouse, rat, dog, minipig, monkey, and human. |
| AID357629 | Cytotoxicity against human HL60 cells after 72 hrs by MTT assay | 2001 | Journal of natural products, Sep, Volume: 64, Issue:9 | Isolation and structure of five new cancer cell growth inhibitory bufadienolides from the Chinese traditional drug Ch'an Su. |
| AID155909 | Inhibitory activity against colchicine resistant parent primary liver carcinoma (PLC) cell line PLC/PRF/5 | 2002 | Journal of medicinal chemistry, Dec-05, Volume: 45, Issue:25 | QSAR evaluation of the Ch'an Su and related bufadienolides against the colchicine-resistant primary liver carcinoma cell line PLC/PRF/5(1). |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
Research
Studies (6)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (33.33) | 29.6817 |
| 2010's | 4 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 12.79
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.79) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 6 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||